Abbott Laboratories

SWX:ABT Stock Report

Market Cap: CHF 175.4b

Abbott Laboratories Valuation

Is ABT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ABT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHF 64.72
Fair Value
53.0% overvalued intrinsic discount
25
Number of Analysts

Below Fair Value: ABT (CHF99) is trading above our estimate of fair value (CHF64.72)

Significantly Below Fair Value: ABT is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABT?

Key metric: As ABT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ABT. This is calculated by dividing ABT's market cap by their current earnings.
What is ABT's PE Ratio?
PE Ratio15.6x
EarningsUS$13.93b
Market CapUS$218.05b

Price to Earnings Ratio vs Peers

How does ABT's PE Ratio compare to its peers?

The above table shows the PE ratio for ABT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.4x
STMN Straumann Holding
34.2x14.42%CHF 14.6b
SOON Sonova Holding
23.2x11.20%CHF 12.1b
MOVE Medacta Group
34x9.47%CHF 3.0b
ALC Alcon
38.1x11.62%CHF 32.1b
ABT Abbott Laboratories
15.6x-7.34%CHF 218.1b

Price-To-Earnings vs Peers: ABT is good value based on its Price-To-Earnings Ratio (15.6x) compared to the peer average (32.4x).

Price to Earnings Ratio vs Industry

How does ABT's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ABT 15.6xIndustry Avg. 25.3xNo. of Companies15PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ABT is good value based on its Price-To-Earnings Ratio (15.6x) compared to the European Medical Equipment industry average (25.4x).

Price to Earnings Ratio vs Fair Ratio

What is ABT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.6x
Fair PE Ratio31.2x

Price-To-Earnings vs Fair Ratio: ABT is good value based on its Price-To-Earnings Ratio (15.6x) compared to the estimated Fair Price-To-Earnings Ratio (31.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ABT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 99.00
CHF 116.24
+17.42%
6.15%CHF 130.38CHF 98.19n/a25
Nov ’26CHF 101.00
CHF 114.60
+13.47%
5.97%CHF 128.51CHF 96.78n/a26
Oct ’26CHF 102.00
CHF 113.88
+11.65%
5.92%CHF 126.72CHF 97.23n/a25
Sep ’26CHF 102.00
CHF 114.01
+11.78%
5.59%CHF 127.23CHF 97.62n/a25
Aug ’26CHF 102.00
CHF 113.27
+11.05%
5.59%CHF 126.40CHF 96.99n/a25
Jul ’26CHF 106.00
CHF 111.98
+5.64%
6.70%CHF 125.99CHF 95.18n/a26
Jun ’26CHF 106.00
CHF 116.27
+9.69%
6.62%CHF 131.51CHF 99.35n/a25
May ’26CHF 106.00
CHF 115.88
+9.32%
7.33%CHF 131.22CHF 91.89n/a25
Apr ’26CHF 93.50
CHF 120.90
+29.30%
8.12%CHF 141.52CHF 98.48n/a24
Mar ’26CHF 93.50
CHF 120.34
+28.71%
7.73%CHF 142.08CHF 98.02n/a24
Feb ’26CHF 93.50
CHF 120.33
+28.69%
7.46%CHF 142.86CHF 98.56n/a24
Jan ’26CHF 93.50
CHF 116.27
+24.36%
7.46%CHF 133.06CHF 92.87n/a24
Dec ’25CHF 93.50
CHF 113.71
+21.62%
7.41%CHF 130.46CHF 91.06CHF 99.0024
Nov ’25CHF 93.50
CHF 111.89
+19.67%
7.56%CHF 126.46CHF 90.08CHF 101.0024
Oct ’25CHF 93.50
CHF 105.18
+12.49%
8.36%CHF 121.01CHF 88.01CHF 102.0023
Sep ’25CHF 92.00
CHF 105.26
+14.41%
8.53%CHF 121.58CHF 88.42CHF 102.0022
Aug ’25CHF 94.00
CHF 110.14
+17.17%
7.98%CHF 126.40CHF 91.93CHF 102.0022
Jul ’25CHF 93.00
CHF 113.07
+21.58%
7.60%CHF 129.19CHF 93.96CHF 106.0022
Jun ’25CHF 93.00
CHF 113.07
+21.58%
7.60%CHF 129.19CHF 93.96CHF 106.0022
May ’25CHF 93.00
CHF 115.18
+23.85%
7.46%CHF 130.37CHF 94.82CHF 106.0022
Apr ’25CHF 93.00
CHF 110.86
+19.21%
7.23%CHF 124.59CHF 91.89CHF 93.5022
Mar ’25CHF 93.00
CHF 109.75
+18.01%
7.25%CHF 123.89CHF 91.38CHF 93.5022
Feb ’25CHF 93.00
CHF 106.82
+14.86%
7.30%CHF 120.94CHF 89.20CHF 93.5021
Jan ’25CHF 93.00
CHF 100.36
+7.92%
7.65%CHF 113.89CHF 85.63CHF 93.5021
Dec ’24CHF 91.00
CHF 104.23
+14.53%
7.94%CHF 119.24CHF 89.66CHF 93.5021
CHF 114.31
Fair Value
13.4% undervalued intrinsic discount
25
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/05 22:52
End of Day Share Price 2025/12/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abbott Laboratories is covered by 55 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Matthew MiksicBarclays
Adam FeinsteinBarclays